-
Rezivertinib Mesylate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Rezivertinib Mesylate Capsules (trade name: 瑞必达) of Beta Pharma (Shanghai) Co., Ltd. is approved for marketing by China NMPA.
-
Crisugabalin Besilate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Crisugabalin Besilate Capsules (trade name: 思美宁) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with diabetic peripheral neuropathic pain.
-
Repotrectinib capsules approved with conditions for marketing by China NMPA
2024-05-11
Recently, the Class 1 innovative drug Repotrectinib Capsules (trade name: 奥凯乐/AUGTYRO) of Bristol-Myers Squibb Company is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
-
China Medical Device Standards Management Annual Report (2023)
2024-05-11
In 2023, China NMPA approved and issued 117 industry standard projects for medical devices, which were divided into formulation projects (57, 48.7%) and revision projects (60, 51.3%) according to the formulation and revision of standards.
-
Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter and Symplicity G3™ Renal Denervation RF Generator Approved for Marketing
2024-04-30
Recently, the innovative products Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter and Symplicity G3™ Renal Denervation RF Generator of Medtronic, Inc. were approved by China NMPA.
-
Entinostat Tablets Approved for Marketing by China NMPA
2024-04-30
Recently, the Category I innovative drug Entinostat Tablets (Chinese trade name: 景助达) of Taizhou EOC Pharma Co. Ltd was approved for marketing by the National Medical Products Administration.
